Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease that lacks effective treatment modalities. Once patients are diagnosed with IPF, their median survival is approximately 3–5 years. PPARγ is an important target for the prevention and treatment of pulmonary fibrosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Qian, Zhou, Ting-ting, Huang, Wen-jie, Huang, Xiao-ting, Huang, Lei, Zhang, Xiao-hua, Sang, Xiao-xue, Luo, Yu-yang, Tian, Yu-mei, Wu, Bin, Liu, Lin, Luo, Zi-qiang, He, Bin, Liu, Wei, Tang, Si-yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485066/
https://www.ncbi.nlm.nih.gov/pubmed/37679587
http://dx.doi.org/10.1038/s41598-023-41933-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485066/
https://www.ncbi.nlm.nih.gov/pubmed/37679587
http://dx.doi.org/10.1038/s41598-023-41933-5

Ejemplares similares